Electroconvulsive Therapy (ECT)

Overview

What ECT Is

ECT is a medical procedure in which a brief, carefully calibrated electrical stimulus is delivered through electrodes on the scalp to induce a generalized tonic-clonic seizure in the brain while the body is paralyzed by a short-acting muscle relaxant and the patient is asleep under general anesthesia. The therapeutic effect comes from the seizure activity in the brain, not from the electrical stimulus itself.

What Modern ECT Is Not

Modern ECT is not delivered to awake, unmedicated patients. Patients are not strapped down for the seizure; muscle relaxation prevents convulsive movements. They are continuously oxygenated and monitored with ECG, EEG, and pulse oximetry. The procedure is typically over within ten to fifteen minutes from entering the procedure room to entering recovery. Memory loss is not total; cognitive effects with current protocols are far smaller than in the techniques of the mid-20th century.

Who Performs ECT

An ECT treatment team includes a psychiatrist trained in ECT, an anesthesiologist or nurse anesthetist, and nursing staff. Treatment is delivered in a hospital procedure suite or a dedicated ECT room with full resuscitation capability.

Patient Path

Patients arrive fasting, are interviewed and consented for the day's treatment, receive intravenous anesthesia and a muscle relaxant, have the seizure induced and monitored, wake in a recovery area, and typically go home a few hours later. Outpatient and inpatient ECT exist; severe cases often begin inpatient and transition to outpatient.

Historical Origins

Early Convulsive Therapies

The therapeutic use of induced seizures predates electrical induction. In the 1930s, Hungarian psychiatrist Ladislas Meduna noted what he believed was an inverse relationship between epilepsy and schizophrenia and induced seizures pharmacologically with camphor and then pentylenetetrazol (Metrazol). Convulsive therapy spread rapidly despite primitive methods and high distress.

Cerletti and Bini, 1938

In Rome in 1938, Ugo Cerletti and Lucio Bini administered the first electrically induced therapeutic seizure to a patient with schizophrenia. Electrical induction was faster, more reliable, and more controllable than pharmacological seizures. ECT spread quickly across Europe and North America in the 1940s as one of the few effective psychiatric treatments available before modern psychotropic medications.

The Era Before Anesthesia

Through the 1940s and into the 1950s, ECT was often delivered without anesthesia or muscle relaxation, producing full convulsive movements with attendant injury risks including spinal fractures. The introduction of succinylcholine for muscle relaxation in the 1950s and general anesthesia made the procedure safer and more humane. Modified ECT — the contemporary standard — refers to ECT delivered under anesthesia with a muscle relaxant.

Backlash and Stigma

By the late 1960s and 1970s, ECT had become associated in the public mind with coercive psychiatric practice, partly through cultural depictions including Ken Kesey's One Flew Over the Cuckoo's Nest and partly through documented abuses. Use declined sharply as antidepressants and antipsychotics became available, and several jurisdictions enacted restrictions.

Modern Re-Evaluation

From the 1980s onward, accumulating evidence on efficacy, refinements in technique (brief pulse, ultrabrief pulse, right unilateral placement), and APA practice guidelines led to a clinical re-evaluation. Today ECT is recognized in international psychiatric guidelines as the most effective acute treatment for severe and certain specific forms of depression and is offered in most academic medical centers. Public misunderstanding nonetheless persists.

How It Works

The Therapeutic Effect Is the Seizure

The clinical effect of ECT depends on inducing an adequate generalized seizure, not on the electrical dose itself. The induced seizure produces widespread changes across cortical and subcortical networks involved in mood regulation.

Proposed Neurobiological Mechanisms

• Modulation of monoamine systems — particularly serotonin and dopamine
• Changes in GABAergic transmission and seizure threshold across the course
• Increased expression of brain-derived neurotrophic factor (BDNF)
• Hippocampal and other regional neuroplastic changes seen on neuroimaging
• Normalization of functional connectivity in mood-related networks
• Neuroendocrine effects on the hypothalamic-pituitary-adrenal axis

No single mechanism fully explains the antidepressant effect; the action is likely multimodal.

Electrode Placement

Three placements are in common use, with different efficacy and cognitive trade-offs:

• Bilateral (bitemporal): Electrodes over both temples. Strongest efficacy, fastest response, and greater cognitive side effects.
• Right unilateral (RUL): One electrode over the right temple and one near the vertex. Reduced cognitive effects; with adequate dose (typically multiples of seizure threshold) and ultrabrief pulse width, efficacy approaches that of bilateral placement.
• Bifrontal: Both electrodes over the frontal regions. Intermediate cognitive profile, growing use in some centers.

Pulse Width

Modern devices deliver brief square-wave pulses rather than the sine-wave currents of older machines. Ultrabrief pulse (0.3 milliseconds or less) is associated with substantially reduced cognitive side effects compared with brief pulse (around 0.5 to 1.0 millisecond). Some efficacy is sacrificed at very short pulse widths, which is balanced against the cognitive benefit.

Seizure Threshold and Dosing

Each patient has a seizure threshold determined at the first treatment (or estimated). Subsequent treatments deliver a stimulus suprathreshold by a multiplier appropriate to the placement (commonly 1.5x for bilateral, 6x or more for right unilateral). Seizure threshold rises over the course of treatment, often requiring upward dose adjustment.

Why a Series of Treatments

A single seizure has limited durable effect. Cumulative neurobiological changes across multiple treatments produce remission. Most patients begin to show improvement after three to six treatments, with maximal response typically around the eighth to twelfth.

What a Typical Course Involves

Pre-Treatment Evaluation

Before the index course begins, the patient undergoes psychiatric assessment, medical clearance, anesthesia evaluation, ECG, and laboratory testing. Cardiac, pulmonary, neurological, and dental status are reviewed. Medications are adjusted as needed — benzodiazepines and anticonvulsants raise seizure threshold and may interfere with treatment; some are reduced or held.

Informed Consent

ECT requires detailed informed consent, often re-affirmed periodically during the course. Consent includes discussion of efficacy, alternatives, expected cognitive effects, anesthesia risks, and the right to stop at any time. For patients unable to consent (for example, severe catatonia or psychosis without capacity), legal pathways vary by jurisdiction and may require court or surrogate involvement.

The Day of Treatment

• Fasting from midnight; small sips of water with morning medications as instructed
• Arrival at the ECT suite, vital signs, intravenous line placement
• Brief check-in with psychiatrist and anesthesiologist
• Anesthesia induction (typically methohexital or propofol) and muscle relaxant (succinylcholine)
• Oxygenation, bite block placement, electrode positioning
• Brief electrical stimulus and induced seizure, monitored by EEG and a "cuff" technique that preserves motor seizure in one limb
• Recovery in a monitored area with nursing oversight
• Discharge home accompanied by a responsible adult; no driving for the rest of the day

Number and Frequency of Treatments

An index course typically involves 6 to 12 treatments delivered two to three times per week, although the exact number is individualized based on response. Treatments stop when remission is achieved or when further response is unlikely. Some patients require more, others fewer.

Continuation and Maintenance ECT

Because relapse after a successful course is common, many patients continue with pharmacotherapy, psychotherapy, or maintenance ECT. Maintenance ECT means periodic single sessions — weekly tapering to monthly — for months to years after the index course, individualized to prevent relapse.

Outpatient vs. Inpatient

Severe presentations — acute suicidality, catatonia, profound food refusal — typically begin inpatient. As patients improve, the course transitions to outpatient. Many patients receive their entire course as outpatients if illness severity and home support permit.

Conditions Treated and Evidence Base

Treatment-Resistant Major Depression

Severe depression, particularly after failure of medication trials, is the most common indication. Across trials and large observational cohorts, ECT achieves response rates in the 60 to 80% range and remission rates higher than essentially any other antidepressant treatment. Response is generally faster than with medications, often within one to two weeks of starting the course.

Depression with Psychotic Features

Psychotic depression responds particularly well to ECT, often with higher remission rates than non-psychotic depression and faster onset. ECT is recommended in major guidelines as a first-line option in severe psychotic depression.

Severe Suicidality

For acutely suicidal patients, ECT can produce rapid improvement — sometimes within days — providing one of the few interventions with that speed of action. It is often used as a bridge while other treatments take effect.

Catatonia

Catatonia of any underlying cause — mood disorder, schizophrenia, medical illness — responds dramatically to ECT, often after lorazepam has failed. Malignant catatonia and neuroleptic malignant syndrome are particular emergencies where ECT can be life-saving.

Severe and Treatment-Resistant Mania

ECT is effective in severe mania, particularly when medication response is incomplete, when delirious mania is present, or when rapid stabilization is needed.

Schizophrenia and Schizoaffective Disorder

ECT is not a first-line treatment for schizophrenia but can be useful for treatment-resistant psychotic symptoms, prominent affective features, or comorbid catatonia. Effectiveness is more modest than in mood disorders.

Parkinson's Disease and Neuroleptic Malignant Syndrome

ECT has been used in Parkinson's-related depression and on-off fluctuations, with reports of improvement in both psychiatric and motor symptoms. In neuroleptic malignant syndrome, ECT has a role when standard medical management is inadequate.

Pregnancy and Postpartum

ECT can be safely delivered during pregnancy and postpartum and is sometimes preferred over medications when the latter carry teratogenic or breastfeeding concerns. Coordination with obstetrics is essential.

Geriatric Patients

Older adults often tolerate ECT well, and response rates in geriatric depression are particularly high. ECT can be safer than polypharmacy in frail older patients.

Where Evidence Is Limited

Anxiety disorders, OCD, and PTSD as primary indications are not standard ECT applications. Personality disorders, by themselves, are not indications. Mild to moderate depression that has not been adequately treated with first-line modalities is not generally an appropriate use.

Risks and Side Effects

Common, Generally Transient

• Post-procedure confusion (usually 15 to 60 minutes)
• Headache
• Muscle soreness from succinylcholine fasciculations
• Nausea
• Jaw soreness

Cognitive Side Effects

Cognitive effects are the most clinically important consideration. They fall into several categories:

• Acute confusion (postictal): Brief disorientation that resolves within an hour.
• Anterograde memory impairment: Difficulty forming new memories during the treatment course. Typically resolves within days to weeks after the course ends.
• Retrograde amnesia: Patchy loss of memories from around the treatment period, sometimes extending months before. Most resolves over weeks to months, but some autobiographical memories around the treatment window can be permanently affected.
• Subjective complaints: Some patients report persistent subjective memory or cognitive concerns beyond what objective testing shows. These are taken seriously and are a real part of the experience for some.

Right unilateral ultrabrief pulse protocols produce substantially fewer cognitive side effects than older bilateral, brief-pulse, or sine-wave techniques. Discussing the trade-off between efficacy and cognitive risk is part of consent.

Anesthesia Risks

Standard general anesthesia risks apply: rare allergic reaction, aspiration, cardiovascular events. The risks of brief general anesthesia for ECT are similar to those for other minor procedures and depend on the patient's overall medical status.

Cardiovascular

Transient blood pressure and heart rate elevation during the seizure occurs. Patients with cardiac disease are evaluated by cardiology before treatment; protocols may be adjusted, but most cardiac patients can receive ECT safely.

Mortality

Mortality rates from modern ECT are very low — estimates around 1 to 4 per 100,000 treatments — comparable to general anesthesia for any short procedure and lower than the mortality risk of untreated severe depression. ECT can be life-saving in life-threatening psychiatric illness.

Contraindications

There are very few absolute contraindications. Relative contraindications include recent myocardial infarction, severely raised intracranial pressure, recent stroke, and unstable major medical conditions. These are assessed case-by-case in consultation with relevant specialists.

Cost, Access, and Insurance

Pricing

Individual ECT treatments in the United States typically cost between $1,000 and $3,000 once anesthesia, professional fees, and facility charges are aggregated. A full index course of 8 to 12 treatments can total $10,000 to $30,000 in retail pricing. Inpatient ECT bundles into broader hospitalization costs.

Insurance Coverage

Medicare, Medicaid, and most commercial insurance plans cover ECT for established indications, particularly treatment-resistant depression, catatonia, and severe suicidality. Prior authorization is sometimes required. Coverage of maintenance ECT and outpatient continuation is generally available but can require ongoing documentation.

Access Barriers

ECT is delivered in academic medical centers and some community hospitals but is not universally available. Rural patients and patients in regions with restrictive state laws or fewer trained psychiatrists may face significant travel. Some jurisdictions have age-related restrictions, court-order requirements, or specific consent procedures.

Logistics

The need for fasting, anesthesia, transportation home, and two-to-three-times-weekly attendance creates logistical challenges. Family or caregiver support is often essential. Time off work is typically needed, at least during the index course.

Comparison with Alternative Treatments

ECT Versus Antidepressants

For mild to moderate depression, medication and psychotherapy are first-line. ECT is reserved for severe depression that has not responded to adequate medication trials, severe depression where rapid response is needed, or depression with features (psychotic, catatonic, severely suicidal) for which ECT outperforms medication.

ECT Versus TMS

TMS is non-invasive, outpatient, requires no anesthesia, and has minimal cognitive side effects, but is less effective than ECT for the most severe forms of depression. The typical sequence is medication trials, then TMS for moderate treatment-resistance, then ECT for severe or life-threatening depression. See our TMS page for the contrast.

ECT Versus Ketamine and Esketamine

Ketamine and intranasal esketamine offer rapid antidepressant onset without anesthesia or seizure induction. Single-dose effects are usually less durable than an ECT course, and abuse potential differs. Comparative trials suggest ECT may be more effective for the most severe presentations; ketamine is gentler and more accessible.

ECT Versus Vagus Nerve Stimulation

VNS is an implanted device approved for treatment-resistant depression with slow onset (months) and modest effect sizes. ECT is faster and more effective acutely; VNS is a long-term option for selected patients.

ECT Versus Deep Brain Stimulation

DBS is invasive, neurosurgical, and largely investigational in psychiatric indications. ECT does not require surgery and has decades of safety data.

ECT Versus No Treatment

The risk profile of ECT must always be compared with the risk profile of untreated severe psychiatric illness, which includes very high suicide risk, profound functional impairment, and significant mortality. For severe presentations, the most dangerous option is often inaction.

Limitations and Controversies

Stigma and Misperception

ECT carries a heavier social stigma than its current safety profile justifies. Patients and families often resist or fear it on the basis of decades-old portrayals. Clinicians have a responsibility to provide accurate information and to address fears directly rather than dismissing them.

Subjective Memory Concerns

A subset of patients reports persistent subjective memory or cognitive complaints that go beyond what neuropsychological testing detects. Whether this reflects subtle effects not captured by standard testing, residual depression-related cognitive complaints, or both is debated. These reports deserve to be heard and not dismissed; informed consent should anticipate them honestly.

Coercion and Consent

Historically, ECT was sometimes delivered without meaningful consent. Modern practice prioritizes informed, voluntary consent and follows specific legal protections for patients without decision-making capacity. Nonetheless, the power dynamics around severely ill patients and their families warrant continuing vigilance.

Relapse

Without maintenance treatment, relapse rates after a successful ECT course are high — on the order of 50% or more within six months. This is a treatment of acute illness; long-term plans must address relapse prevention.

Access Inequities

ECT availability varies widely across regions, hospital systems, and insurance contexts. State laws in some jurisdictions restrict use or impose extra procedural hurdles, which can put effective treatment further out of reach for some patients.

Activist and Survivor Voices

Some former ECT patients describe profound negative experiences, including significant memory loss and a feeling of being changed by the treatment. Their perspectives are part of the picture and should be engaged seriously alongside clinical evidence rather than dismissed.

Mechanism Still Incompletely Understood

Despite eight decades of clinical use, the precise mechanism by which an induced seizure relieves depression remains uncertain. The treatment works; the explanation continues to mature.

Pediatric Use

ECT is used in adolescents with severe, life-threatening psychiatric illness — particularly catatonia and treatment-resistant depression — though it remains rare and is regulated more tightly. Outcomes are generally favorable but data are sparser than in adults.

What to Expect

Deciding to Pursue ECT

The decision typically follows multiple unsuccessful medication trials, severe symptoms, or features that specifically favor ECT (psychotic depression, catatonia, severe suicidality). Discussion with the psychiatrist should include realistic expectations of efficacy, expected cognitive effects, the schedule, and what maintenance might look like.

Before the First Treatment

Expect a thorough medical and psychiatric workup, anesthesia review, dental check, and detailed consent. Medications may be adjusted. Practical planning — transportation, time off, household support — is essential.

The Procedure

Patients are awake until anesthesia is given. They wake in recovery, usually feeling groggy and sometimes briefly confused. Most go home a few hours after the procedure. The induced seizure itself is not consciously experienced.

Across the Course

Mood improvement typically begins within the first one to two weeks. Family members often notice changes before the patient does — improved sleep, more engagement, decreased rumination. Memory may feel patchy during the course; orientation around current events sometimes lags.

After the Course

Cognitive recovery proceeds over days to weeks for most patients. A clear maintenance plan — medications, psychotherapy, and possibly continuation ECT — is critical because relapse rates without it are high.

Practical Recommendations

• Keep a written record of major appointments and events during the course; memory for them may be patchy
• Avoid major life decisions during the index course
• Have a trusted person attend pre-treatment discussions and recovery
• Discuss memory and cognitive concerns openly with the treatment team — adjustments to placement, pulse width, or frequency are possible
• Plan for a structured return to driving, work, and daily activities